Liminal Biosciences Inc. (LMNL) News
Filter LMNL News Items
LMNL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LMNL News Highlights
- For LMNL, its 30 day story count is now at 2.
- Over the past 1 day, the trend for LMNL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AGRX, ARGX and SE are the most mentioned tickers in articles about LMNL.
Latest LMNL News From Around the Web
Below are the latest news stories about Liminal BioSciences Inc that investors may wish to consider to help them evaluate LMNL as an investment opportunity.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agile Therapeutics (AGRX), Argenx Se (ARGX) and Liminal BioSciences (LMNL)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRX – Research Report), Argenx Se (ARGX – Research Report) and Liminal BioSciences (LMNL – Research Report). Agile Therapeutics (AGRX) In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $2.50. The company's shares closed last Wednesday at $0.34, close to its 52-week low of $0.34. According to TipRanks. |
Liminal BioSciences Announces Strategic Priorities For 2022Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022. |
Liminal BioSciences Reports Third Quarter 2021 Financial ResultsLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the third quarter ended September 30, 2021. |
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseLiminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics BusinessLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion"). |
Liminal BioSciences Announces Closing of Sale of Priority Review VoucherLiminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million. |
After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayGood morning, investor! |
Liminal BioSciences Reports Second Quarter 2021 Financial ResultsLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the second quarter ended June 30, 2021. |
Liminal BioSciences Announces Sale of Priority Review Voucher for USD105MLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for USD105M. |